Evidence map›Paper›PMID 34681940›Full record

ArticleInternational journal of molecular sciences2021

Synthesis and Inhibition Activity Study of Triazinyl-Substituted Amino(alkyl)-benzenesulfonamide Conjugates with Polar and Hydrophobic Amino Acids as Inhibitors of Human Carbonic Anhydrases I, II, IV, IX, and XII.

Mária Bodnár Mikulová, Dáša Kružlicová, Daniel Pecher, Andrea Petreni, Claudiu T Supuran, Peter Mikuš

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mária Bodnár MikulováDepartment of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia.
Dáša KružlicováDepartment of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia.
Daniel PecherDepartment of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia.ORCID 0000-0002-9284-1493
Andrea PetreniNeurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, University of Florence, 50139 Florence, Italy.
Claudiu T SupuranNeurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, University of Florence, 50139 Florence, Italy.ORCID 0000-0003-4262-0323
Peter MikušDepartment of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia.ORCID 0000-0001-5755-9970
Comenius University Bratislava · SKUniversity of Florence · IT

Funding

KEGA KEGA 027UK-4/2020Slovak Research and Development Agency APVV-15-0585VEGA VEGA 1/0463/18
6 · The paper itself

Abstract

Primary sulfonamide derivatives with various heterocycles represent the most widespread group of potential human carbonic anhydrase (hCA) inhibitors with high affinity and selectivity towards specific isozymes from the hCA family. In this work, new 4-aminomethyl- and aminoethyl-benzenesulfonamide derivatives with 1,3,5-triazine disubstituted with a pair of identical amino acids, possessing a polar (Ser, Thr, Asn, Gln) and non-polar (Ala, Tyr, Trp) side chain, have been synthesized. The optimized synthetic, purification, and isolation procedures provided several pronounced benefits such as a short reaction time (in sodium bicarbonate aqueous medium), satisfactory yields for the majority of new products (20.6-91.8%, average 60.4%), an effective, well defined semi-preparative RP-C18 liquid chromatography (LC) isolation of desired products with a high purity (>97%), as well as preservation of green chemistry principles. These newly synthesized conjugates, plus their 4-aminobenzenesulfonamide analogues prepared previously, have been investigated in in vitro inhibition studies towards hCA I, II, IV and tumor-associated isozymes IX and XII. The experimental results revealed the strongest inhibition of hCA XII with low nanomolar inhibitory constants (K

Indexed as

Amino AcidsAntigens, NeoplasmBenzenesulfonamidesCarbonic Anhydrase ICarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarbonic Anhydrase IVCarbonic Anhydrase IXCarbonic AnhydrasesCarrier ProteinsHumansHydrophobic and Hydrophilic InteractionsNerve Tissue ProteinsSulfonamidesTriazinesAmino AcidsAntigens, NeoplasmBenzenesulfonamidesCA1 carbonic anhydrase, humanCA2 protein, humanCA4 protein, humanCA9 protein, humanCarbonic Anhydrase ICarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarbonic Anhydrase IVCarbonic Anhydrase IXCarbonic Anhydrasescarbonic anhydrase XIICarrier ProteinsNerve Tissue ProteinsSulfonamidesTriazines1,3,5-triazineamino acidsbenzenesulfonamidehuman carbonic anhydrasehybrid moleculeinhibition

Identifiers

PMID34681940
PMCPMC8537140
OpenAlexW3205498894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.